Clinical trial
A Phase 3, Multicenter, Randomized, Open-Label Trial of Raludotatug Deruxtecan With or Without Bevacizumab as Maintenance Therapy Versus Standard of Care in Participants With First Recurrence Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (REJOICE-Ovarian03)
NCT07791732 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Multicenter, Randomized, Open-Label Trial of Raludotatug Deruxtecan With or Without Bevacizumab as Maintenance Therapy Versus Standard of Care in Participants With First Recurrence Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (REJOICE-Ovarian03)
- Lead sponsor
- Daiichi Sankyo
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- October 1, 2026
- Completion date
- December 1, 2033
- Enrollment
- 600 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
endometrioid epithelial ovarian, fallopian tube cancer, high-grade serous ovarian cancer, primary peritoneal cancer